“Balance” seems to be the keyword for the next drug pricing reform in FY2024. Japan now appears ready to seek a better balance between evaluating innovative medicines and taking tough measures against companies dependent on long-listed products (LLPs) and generic…
HOME > COLUMN
COLUMN
-
Failing Isn’t the Issue. What You Do Next Is All that Counts
July 26, 2019
-
Big Question Mark to Pricey Drug Bashing
July 12, 2019
-
The Science Behind Stage Fright, and How You Can Overcome It
June 28, 2019
-
The Power in Teaching Your Team “How to Speak”
May 28, 2019
-
Unlock Hidden Talent by Hiring for These Four Traits
May 10, 2019
-
No Drug “Reviews” for 1st Time in 2 Years
April 22, 2019
-
6 Core Elements of Recruitment Mastery
March 22, 2019
-
Is Japan’s Cost-Effectiveness Assessment Scheme Cost Effective?
February 27, 2019
-
Why Top-Tier Recruiters Must Embrace Their Creative Side
January 31, 2019
-
Expat Truths from the Japanese Medical Device World
December 3, 2018
-
Why Did the Project Take so Long?
November 16, 2018
-
Why Did the Project Take so Long?
November 16, 2018
-
Finding Captains in Your Organization
October 12, 2018
-
Riding the Trend: Staffing Pharma Startups in Japan
September 7, 2018
-
How Having a Great CSR Program Can Help with Recruiting and Retaining Top Talent
August 16, 2018
-
Rare Disease Pharmaceuticals in Japan to See New Demand for Skilled Human Resources
July 20, 2018
-
5 Billion Yen Blockbuster?
June 20, 2018
-
It Is Thumbs Up for Cell Therapy in Japan
March 23, 2018
-
Unique Opportunities at Pharmaceutical Companies Treating Rare Diseases
February 23, 2018
-
When Leading Teams, Focus on the Principles, Not the Personalities
January 26, 2018
ページ
Companies don’t plan to fail when it comes to recruitment, but many fail to plan. What happens if your marketing director resigns? A recruiting plan gives your organization the confidence in knowing that whatever happens, there is a process in…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…